Trial Profile
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Chiglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CMAP
- Sponsors Chipscreen Biosciences
- 26 Jun 2023 Results of post-hoc analysis from CMAP and CAMS identifying the subgroup with higher benefits with chiglitazar, using a machine learning algorithm , presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 19 Oct 2021 Results published in the Chipscreen Biosciences Media Release.
- 19 Oct 2021 According to a Chipscreen Biosciences media release, Bilessglu (Chiglitazar Sodium tablets) has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of Type 2 Diabetes (T2DM). The approval is based on CMAS and CMAP studies.